Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBS NASDAQ:INVA NYSE:JNJ NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$8.08-4.2%$8.41$5.61▼$14.06$435.47M2.33758,648 shs700,321 shsINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.64B0.35870,504 shs845,393 shsJNJJohnson & Johnson$232.81+2.0%$231.98$149.04▼$251.71$549.25B0.267.30 million shs8.02 million shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions+7.04%-7.92%-6.81%+1.81%+32.91%INVAInnoviva+2.12%+1.23%-2.16%+0.59%+6.13%JNJJohnson & Johnson+2.11%-1.17%+1.21%-5.09%+48.85%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$8.08-4.2%$8.41$5.61▼$14.06$435.47M2.33758,648 shs700,321 shsINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.64B0.35870,504 shs845,393 shsJNJJohnson & Johnson$232.81+2.0%$231.98$149.04▼$251.71$549.25B0.267.30 million shs8.02 million shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions+7.04%-7.92%-6.81%+1.81%+32.91%INVAInnoviva+2.12%+1.23%-2.16%+0.59%+6.13%JNJJohnson & Johnson+2.11%-1.17%+1.21%-5.09%+48.85%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent Biosolutions 2.40Hold$12.0048.46% UpsideINVAInnoviva 2.57Moderate Buy$36.2060.75% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.048.69% UpsideNVAXNovavax 2.10Hold$12.1327.77% UpsideCurrent Analyst Ratings BreakdownLatest EBS, JNJ, NVAX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026EBSEmergent Biosolutions UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026EBSEmergent Biosolutions BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/11/2026EBSEmergent Biosolutions Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/27/2026EBSEmergent Biosolutions Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent Biosolutions$742.90M0.56$3.51 per share2.30$9.95 per share0.81INVAInnoviva$411.33M4.04$5.12 per share4.40$15.71 per share1.43JNJJohnson & Johnson$94.19B5.95$14.41 per share16.16$33.85 per share6.88NVAXNovavax$1.12B1.39$3.27 per share2.90($0.79) per share-12.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent Biosolutions$52.60M-$0.28N/AN/AN/A-1.27%10.76%4.22%8/5/2026 (Estimated)INVAInnoviva$271.17M$6.013.759.27N/A119.89%33.33%22.67%8/5/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.9118.482.2421.83%32.60%13.29%7/15/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest EBS, JNJ, NVAX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million4/30/2026Q1 2026EBSEmergent Biosolutions-$0.25$0.21+$0.46$0.07$145.00 million$156.10 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BiosolutionsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.362.30%+5.25%61.97%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest EBS, JNJ, NVAX, and INVA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent Biosolutions1.104.292.08INVAInnoviva0.1921.1320.07JNJJohnson & Johnson0.461.030.77NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent Biosolutions78.40%INVAInnoviva99.12%JNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipEBSEmergent Biosolutions6.00%INVAInnoviva2.01%JNJJohnson & Johnson0.16%NVAXNovavax1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent Biosolutions2,42051.60 million48.50 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableEBS, JNJ, NVAX, and INVA HeadlinesRecent News About These CompaniesNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?4 hours ago | finance.yahoo.comNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?June 5 at 12:35 PM | zacks.comNovavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older AdultsJune 5 at 12:31 PM | tipranks.com3 Cash-Burning Stocks We Think Twice AboutJune 4 at 3:44 PM | finance.yahoo.comNovavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4 at 2:03 PM | seekingalpha.comNovavax, Inc. (NASDAQ:NVAX) Receives Average Rating of "Hold" from BrokeragesJune 3 at 2:04 AM | americanbankingnews.comNovavax Inc. stock underperforms Monday when compared to competitorsJune 1, 2026 | marketwatch.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | finance.yahoo.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | prnewswire.comWall Street Zen Upgrades Novavax (NASDAQ:NVAX) to HoldMay 31, 2026 | americanbankingnews.comNovavax: The Pivot To A Royalty Model Is Working, But It's Still A HoldMay 30, 2026 | seekingalpha.comWhy Novavax (NVAX) Stock Is Trading Up TodayMay 26, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItMay 26, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItMay 26, 2026 | zacks.com3 Reasons NVAX is Risky and 1 Stock to Buy InsteadMay 25, 2026 | finance.yahoo.comZacks Research Issues Negative Outlook for Novavax EarningsMay 25, 2026 | americanbankingnews.comNovavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should WatchMay 22, 2026 | tipranks.com3 Small-Cap Stocks That Fall ShortMay 18, 2026 | finance.yahoo.comAssessing Novavax (NVAX) Valuation As Trading Swings Revive Investor InterestMay 18, 2026 | finance.yahoo.comGoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To KnowMay 17, 2026 | finance.yahoo.comVanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAXMay 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026EBS, JNJ, NVAX, and INVA Company DescriptionsEmergent Biosolutions NYSE:EBS$8.08 -0.36 (-4.23%) Closing price 03:59 PM EasternExtended Trading$8.21 +0.13 (+1.57%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Innoviva NASDAQ:INVA$22.52 +0.36 (+1.62%) Closing price 04:00 PM EasternExtended Trading$22.52 +0.00 (+0.02%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Johnson & Johnson NYSE:JNJ$232.81 +4.64 (+2.03%) Closing price 03:59 PM EasternExtended Trading$232.28 -0.53 (-0.23%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$9.49 -0.70 (-6.87%) Closing price 04:00 PM EasternExtended Trading$9.39 -0.10 (-1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
